GILD Factor-Based Stock Analysis

Gilead Sciences (GILD) received an 80% rating from Validea's Earnings Yield Investor model, based on Joel Greenblatt's 'Magic Formula' strategy which targets high return on capital and earnings yields. While this score typically indicates 'some interest,' the detailed analysis within the model shows a 'FINAL RANKING: FAIL' for GILD, with both earnings yield and return on tangible capital being 'NEUTRAL.' This suggests that despite the initial high-level score, the stock ultimately does not fully meet the stringent criteria of this value-oriented quantitative strategy.

Analysis

Gilead Sciences, Inc. (GILD) presents a conflicting profile under Validea's quantitative model based on Joel Greenblatt's 'Magic Formula' strategy. While the stock achieves an initial rating of 80%, a score that typically indicates some level of interest, it ultimately receives a 'FAIL' in the final ranking. This failure is directly attributable to the stock's 'NEUTRAL' ratings on the two core pillars of the strategy: Earnings Yield and Return on Tangible Capital. This suggests that GILD does not currently exhibit the combination of high yield and high return on capital required to pass the stringent criteria of this specific value-oriented approach. The mixed-to-negative sentiment score (-0.2 for GILD) reflects this outcome, where an encouraging top-line score is invalidated by a failure in the underlying fundamental tests.

Key Decisions for Investors

• Investors employing quantitative value strategies, particularly the Greenblatt model, should note that GILD fails the detailed screening criteria despite a superficially attractive high-level score.
• The 'NEUTRAL' ratings on both earnings yield and return on tangible capital highlight specific areas of fundamental weakness that warrant deeper due diligence before initiating or adding to a position.
• Consider this 'FAIL' rating as a single, specific data point from one quantitative model, which should be weighed against broader fundamental analysis and other valuation methodologies rather than being treated as a standalone trading signal.